Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17.

PMID:
30559106
2.

Emergence of tick-borne encephalitis (TBE) in the Netherlands.

Dekker M, Laverman GD, de Vries A, Reimerink J, Geeraedts F.

Ticks Tick Borne Dis. 2019 Jan;10(1):176-179. doi: 10.1016/j.ttbdis.2018.10.008. Epub 2018 Oct 25.

PMID:
30385073
3.

Detection of carnosinase-1 in urine of healthy individuals and patients with type 2 diabetes: correlation with albuminuria and renal function.

Rodriguez-Niño A, Gant CM, Braun JD, Li X, Zhang S, Albrecht T, Qiu J, Bakker SJL, Laverman GD, Krämer BK, Herold A, Hauske SJ, Yard BA.

Amino Acids. 2018 Jun 30. doi: 10.1007/s00726-018-2602-y. [Epub ahead of print]

PMID:
29961141
4.

Lower Renal Function Is Associated With Derangement of 11-β Hydroxysteroid Dehydrogenase in Type 2 Diabetes.

Gant CM, Minovic I, Binnenmars H, de Vries L, Kema I, van Beek A, Navis G, Bakker S, Laverman GD.

J Endocr Soc. 2018 May 22;2(7):609-620. doi: 10.1210/js.2018-00088. eCollection 2018 Jul 1.

5.

Correlations between plasma strontium concentration, components of calcium and phosphate metabolism and renal function in type 2 diabetes mellitus.

van den Berkhof YS, Gant CM, Maatman R, De Graaf A, Navis GJ, Bakker SJL, Laverman GD.

Eur J Clin Invest. 2018 Sep;48(9):e12987. doi: 10.1111/eci.12987. Epub 2018 Jul 20.

PMID:
29931675
6.

Glycaemic control in the diabetes and Lifestyle Cohort Twente: A cross-sectional assessment of lifestyle and pharmacological management on Hba1c target achievement.

Jalving AC, Gant CM, Binnenmars SH, Soedamah-Muthu SS, Bakker SJL, Navis G, Laverman GD.

Diabetes Obes Metab. 2018 Oct;20(10):2494-2499. doi: 10.1111/dom.13399. Epub 2018 Jun 26.

7.

Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors.

Gant CM, Binnenmars SH, Harmelink M, Soedamah-Muthu SS, Bakker SJL, Navis G, Laverman GD.

Nutr Diabetes. 2018 Apr 25;8(1):24. doi: 10.1038/s41387-018-0028-y.

8.

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.

Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL.

Diabetes Obes Metab. 2018 Aug;20(8):1988-1993. doi: 10.1111/dom.13301. Epub 2018 Apr 23.

9.

Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes.

Gant CM, Soedamah-Muthu SS, Binnenmars SH, Bakker SJL, Navis G, Laverman GD.

Nutrients. 2018 Mar 5;10(3). pii: E307. doi: 10.3390/nu10030307.

10.

Physical Activity in Patients With Type 2 Diabetes: The Case for Objective Measurement in Routine Clinical Care.

Oosterom N, Gant CM, Ruiterkamp N, van Beijnum BF, Hermens H, Bakker SJL, Navis G, Vollenbroek-Hutten MMR, Laverman GD.

Diabetes Care. 2018 Apr;41(4):e50-e51. doi: 10.2337/dc17-2041. Epub 2018 Feb 6. No abstract available.

PMID:
29432126
11.

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.

Gant CM, Laverman GD, Vogt L, Slagman MCJ, Heerspink HJL, Waanders F, Hemmelder MH, Navis G; Holland Nephrology Study (HONEST) Network.

BMC Nephrol. 2017 Dec 20;18(1):370. doi: 10.1186/s12882-017-0789-x.

12.

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

Petrykiv SI, Laverman GD, Persson F, Vogt L, Rossing P, de Borst MH, Gansevoort RT, de Zeeuw D, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1804-1813. doi: 10.2215/CJN.00390117. Epub 2017 Oct 11. Review.

13.

Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

Petrykiv S, Laverman GD, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Jan;20(1):224-227. doi: 10.1111/dom.13057. Epub 2017 Aug 8.

PMID:
28685934
14.

Integrated Assessment of Pharmacological and Nutritional Cardiovascular Risk Management: Blood Pressure Control in the DIAbetes and LifEstyle Cohort Twente (DIALECT).

Gant CM, Binnenmars SH, Berg EVD, Bakker SJL, Navis G, Laverman GD.

Nutrients. 2017 Jul 6;9(7). pii: E709. doi: 10.3390/nu9070709.

15.

Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects.

Toering TJ, Gant CM, Visser FW, van der Graaf AM, Laverman GD, Danser AHJ, Faas MM, Navis G, Lely AT.

Am J Physiol Renal Physiol. 2018 May 1;314(5):F873-F878. doi: 10.1152/ajprenal.00109.2017. Epub 2017 Jun 7.

PMID:
28592435
16.

Increasing evidence of tick-borne encephalitis (TBE) virus transmission, the Netherlands, June 2016.

Weststrate AC, Knapen D, Laverman GD, Schot B, Prick JJ, Spit SA, Reimerink J, Rockx B, Geeraedts F.

Euro Surveill. 2017 Mar 16;22(11). pii: 30482. doi: 10.2807/1560-7917.ES.2017.22.11.30482.

17.

The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.

Petrykiv SI, Laverman GD, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2017 Oct;19(10):1363-1370. doi: 10.1111/dom.12936. Epub 2017 Jun 8.

PMID:
28295959
18.

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.

Kwakernaak AJ, Roksnoer LC, Lambers Heerspink HJ, van den Berg-Garrelds I, Lochorn GA, van Embden Andres JH, Klijn MA, Kobori H, Danser AH, Laverman GD, Navis GJ.

PLoS One. 2017 Jan 24;12(1):e0169258. doi: 10.1371/journal.pone.0169258. eCollection 2017.

19.

Variability in response to albuminuria-lowering drugs: true or random?

Petrykiv SI, de Zeeuw D, Persson F, Rossing P, Gansevoort RT, Laverman GD, Heerspink HJL.

Br J Clin Pharmacol. 2017 Jun;83(6):1197-1204. doi: 10.1111/bcp.13217. Epub 2017 Feb 1.

20.

Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.

Keyzer CA, van Breda GF, Vervloet MG, de Jong MA, Laverman GD, Hemmelder MH, Janssen WM, Lambers Heerspink HJ, Kwakernaak AJ, Bakker SJ, Navis G, de Borst MH; Holland Nephrology Study (HONEST) Network.

J Am Soc Nephrol. 2017 Apr;28(4):1296-1305. doi: 10.1681/ASN.2016040407. Epub 2016 Nov 17.

21.

Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions.

Humalda JK, Keyzer CA, Binnenmars SH, Kwakernaak AJ, Slagman MC, Laverman GD, Bakker SJ, de Borst MH, Navis GJ.

Nutr Metab Cardiovasc Dis. 2016 Aug;26(8):689-96. doi: 10.1016/j.numecd.2016.04.012. Epub 2016 Apr 27.

PMID:
27266988
22.

Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol.

Keyzer CA, de Jong MA, Fenna van Breda G, Vervloet MG, Laverman GD, Hemmelder M, Janssen WM, Lambers Heerspink HJ, Navis G, de Borst MH; Holland Nephrology Study (HONEST) Network.

Nephrol Dial Transplant. 2016 Jul;31(7):1081-7. doi: 10.1093/ndt/gfv033. Epub 2015 Mar 4. Review.

PMID:
25744274
23.

Distal renal tubular acidosis with multiorgan autoimmunity: a case report.

van den Wildenberg MJ, Hoorn EJ, Mohebbi N, Wagner CA, Woittiez AJ, de Vries PA, Laverman GD.

Am J Kidney Dis. 2015 Apr;65(4):607-10. doi: 10.1053/j.ajkd.2014.09.026. Epub 2014 Dec 18.

24.

Bilateral dacryoadenitis as a presenting symptom of an extra-ocular disease.

van den Wildenberg MJ, Laverman GD, de Vries PA.

Neth J Med. 2014 Jun;72(5):281, 285. No abstract available.

25.

Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.

Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, Groen H, Laverman GD, Navis G; Holland Nephrology Study (HONEST) Group.

Lancet Diabetes Endocrinol. 2014 May;2(5):385-95. doi: 10.1016/S2213-8587(14)70030-0. Epub 2014 Mar 5.

PMID:
24795252
26.

A false-positive antineutrophil cytoplasmic antibody proteinase 3 test in a patient with pulmonary-renal syndrome.

Agterhuis DE, Mulder AH, Roozendaal C, Stegeman CA, Laverman GD.

J Rheumatol. 2014 May;41(5):1031-3. doi: 10.3899/jrheum.131205. No abstract available.

PMID:
24788467
27.

Quiz page February 2014: swollen kidneys and a pancreatic mass.

Agterhuis DE, Schuurmans EP, Hogenes MC, Laverman GD.

Am J Kidney Dis. 2014 Feb;63(2):A18-21. doi: 10.1053/j.ajkd.2013.06.030. No abstract available.

PMID:
24461682
28.

The Biobank of Nephrological Diseases in the Netherlands cohort: the String of Pearls Initiative collaboration on chronic kidney disease in the university medical centers in the Netherlands.

Navis GJ, Blankestijn PJ, Deegens J, De Fijter JW, Homan van der Heide JJ, Rabelink T, Krediet RT, Kwakernaak AJ, Laverman GD, Leunissen KM, van Paassen P, Vervloet MG, Wee PM, Wetzels JF, Zietse R, van Ittersum FJ; BIND-NL investigators.

Nephrol Dial Transplant. 2014 Jun;29(6):1145-50. doi: 10.1093/ndt/gft307. Epub 2013 Oct 22. Review.

PMID:
24151018
29.

Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism.

Boumans D, de Vries PA, Rikken NE, Laverman GD.

Neth J Med. 2013 Oct;71(8):442-3. No abstract available.

30.

Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.

Kwakernaak AJ, Waanders F, Slagman MC, Dokter MM, Laverman GD, de Boer RA, Navis G.

J Hypertens. 2013 Dec;31(12):2425-32. doi: 10.1097/HJH.0b013e328364f5de.

PMID:
24029871
31.

Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.

Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP.

Atherosclerosis. 2013 Feb;226(2):459-65. doi: 10.1016/j.atherosclerosis.2012.11.009. Epub 2012 Nov 29.

PMID:
23261172
32.

Vitamin k intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients.

Boxma PY, van den Berg E, Geleijnse JM, Laverman GD, Schurgers LJ, Vermeer C, Kema IP, Muskiet FA, Navis G, Bakker SJ, de Borst MH.

PLoS One. 2012;7(10):e47991. doi: 10.1371/journal.pone.0047991. Epub 2012 Oct 31.

33.

A spangled colon.

Raghoo R, Laverman GD, Woittiez AJ, van den Hout JH, de Vries PA.

Neth J Med. 2012 Oct;70(8):376-80. No abstract available.

34.

Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid.

Boersma MN, van der Zanden A, Laverman GD, Sanders JS, de Vries PA.

Transpl Int. 2012 Nov;25(11):e113-6. doi: 10.1111/j.1432-2277.2012.01552.x. Epub 2012 Aug 21.

35.

Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis.

de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, Navis G.

PLoS One. 2012;7(5):e37957. doi: 10.1371/journal.pone.0037957. Epub 2012 May 25.

36.

Vitamin K intake and status are low in hemodialysis patients.

Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD.

Kidney Int. 2012 Sep;82(5):605-10. doi: 10.1038/ki.2012.191. Epub 2012 May 30.

37.

An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.

Smink PA, Bakker SJ, Laverman GD, Berl T, Cooper ME, de Zeeuw D, Lambers Heerspink HJ.

J Hypertens. 2012 May;30(5):1022-8. doi: 10.1097/HJH.0b013e32835200f9.

PMID:
22388234
38.

The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria.

Mahmoodi BK, Mulder AB, Waanders F, Spronk HM, Mulder R, Slagman MC, Vogt L, Navis G, Ten Cate H, Kluin-Nelemans HC, Laverman GD.

J Thromb Haemost. 2011 Dec;9(12):2416-23. doi: 10.1111/j.1538-7836.2011.04525.x.

39.

Improvement of sodium status to optimize the efficacy of Renin-Angiotensin system blockade.

Laverman GD, Navis G.

Curr Hypertens Rep. 2011 Dec;13(6):397-9. doi: 10.1007/s11906-011-0234-7.

40.

Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.

Slagman MC, Waanders F, Vogt L, Damman K, Hemmelder M, Navis G, Laverman GD.

Nephrol Dial Transplant. 2012 Mar;27(3):983-90. doi: 10.1093/ndt/gfr408. Epub 2011 Aug 22.

PMID:
21862455
41.

Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.

Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, Navis G, Laverman GD; HOlland NEphrology STudy Group.

BMJ. 2011 Jul 26;343:d4366. doi: 10.1136/bmj.d4366.

42.

Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy.

Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD, Goldschmeding R, Navis G.

Clin J Am Soc Nephrol. 2011 Aug;6(8):1845-50. doi: 10.2215/CJN.08190910. Epub 2011 Jul 22.

43.

Vascular endothelial growth factor C levels are modulated by dietary salt intake in proteinuric chronic kidney disease patients and in healthy subjects.

Slagman MC, Kwakernaak AJ, Yazdani S, Laverman GD, van den Born J, Titze J, Navis G.

Nephrol Dial Transplant. 2012 Mar;27(3):978-82. doi: 10.1093/ndt/gfr402. Epub 2011 Jul 21.

PMID:
21778278
44.

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.

Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ.

Hypertension. 2011 Jul;58(1):2-7. doi: 10.1161/HYPERTENSIONAHA.111.171488. Epub 2011 May 31.

PMID:
21632472
45.

Performance of MDRD study and CKD-EPI equations for long-term follow-up of nondiabetic patients with chronic kidney disease.

Tent H, Waanders F, Krikken JA, Heerspink HJ, Stevens LA, Laverman GD, Navis G.

Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii89-95. doi: 10.1093/ndt/gfr235. Epub 2011 May 11.

PMID:
21562145
46.

Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.

Waanders F, de Vries LV, van Goor H, Hillebrands JL, Laverman GD, Bakker SJ, Navis G.

Curr Vasc Pharmacol. 2011 Sep;9(5):594-605. Review.

PMID:
21529330
47.

Circulating matrix γ-carboxyglutamate protein (MGP) species are refractory to vitamin K treatment in a new case of Keutel syndrome.

Cranenburg EC, VAN Spaendonck-Zwarts KY, Bonafe L, Mittaz Crettol L, Rödiger LA, Dikkers FG, VAN Essen AJ, Superti-Furga A, Alexandrakis E, Vermeer C, Schurgers LJ, Laverman GD.

J Thromb Haemost. 2011 Jun;9(6):1225-35. doi: 10.1111/j.1538-7836.2011.04263.x.

48.

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ.

Eur Heart J. 2011 Jun;32(12):1493-9. doi: 10.1093/eurheartj/ehr017. Epub 2011 Mar 18.

PMID:
21421598
49.

Time for a comeback of NSAIDs in proteinuric chronic kidney disease?

Vogt L, Laverman GD, Navis G.

Neth J Med. 2010 Dec;68(12):400-7. Review.

50.

A 33-year-old man presenting with rectal ulceration and nephrotic syndrome.

Boslooper K, Laverman GD, van der Heide H, Tiebosch AT, Janssen WM.

Neth J Med. 2010 Nov;68(11):373, 377. No abstract available.

PMID:
21116034

Supplemental Content

Loading ...
Support Center